Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16030469 | 0.90 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL16030467 | 0.90 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL16090791 | 0.86 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL16156238 | 0.76 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL16031748 | 0.76 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16031746 | 0.76 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16090774 | 0.75 | BRPF1 (0.34) | — | |
| SCHEMBL16090776 | 0.72 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL16090780 | 0.66 | CNR2 (0.33) | MEN1KMT2A | |
| SCHEMBL16030138 | 0.64 | NR1H2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | MEN1 4/4885KMT2A 6/4885 |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | MEN1 4/4885KMT2A 6/4885 |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | MEN1 9/4885KMT2A 11/4885 |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | MEN1 15/4885KMT2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.